Selective versus nonselective β-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
作者: Michael R. BristowArthur M. FeldmanKirkwood F. AdamsSidney Goldstein
作者单位: 1From the 1 University of Colorado Health Sciences Center, Denver, Colorado; 2 Jefferson Medical College, Philadelphia, Pennsylvania; 3 University of North Carolina School of Medicine, Chapel Hill, North Carolina; and the 4 Henry Ford Hospital, Detroit, Michigan USA
刊名: Journal of Cardiac Failure, 2003, Vol.9 (6), pp.444-453
来源数据库: Elsevier Journal
DOI: 10.1016/j.cardfail.2003.10.009
关键词: Β-blockerCarvedilolMetoprololHeart failure
原始语种摘要: Abstract(#br)The recently reported COMET trial found that the β1/β2/α1 receptor blocking agent carvedilol given in a relatively high β1-receptor blocking dose regimen was superior in mortality reduction to immediate release metoprolol given in a relatively low β1-receptor blocking dose schedule. We analyze the problems with the trial design of COMET from the standpoint of comparing 2 therapeutic agents at different positions on a common dose-response curve, and discuss the theoretical reasons why postjunctional adrenergic receptor blockade that is in addition to β1-receptor antagonism will likely produce only minimal or no incremental benefit in chronic heart failure.
全文获取路径: Elsevier  (合作)
影响因子:3.32 (2012)

  • COMET COmputer MEssage Transmission
  • nonselective 不选择的
  • trial 试验
  • blockade 封闭
  • failure 破坏
  • learned 有学识的
  • heart 心脏
  • versus 
  • receptor 接受体
  • metoprolol 美托洛尔